DE602004020073D1 - 3-substituierte imidazopyridinderivate als c-kit-inhibitoren - Google Patents

3-substituierte imidazopyridinderivate als c-kit-inhibitoren

Info

Publication number
DE602004020073D1
DE602004020073D1 DE602004020073T DE602004020073T DE602004020073D1 DE 602004020073 D1 DE602004020073 D1 DE 602004020073D1 DE 602004020073 T DE602004020073 T DE 602004020073T DE 602004020073 T DE602004020073 T DE 602004020073T DE 602004020073 D1 DE602004020073 D1 DE 602004020073D1
Authority
DE
Germany
Prior art keywords
kit inhibitors
imidazopyridine derivatives
substituted imidazopyridine
substituted
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004020073T
Other languages
English (en)
Inventor
Arlindo L Castelhano
Andrew Phillip Crew
Han-Qing Dong
Radoslaw Laufer
An-Hu Li
Li Qiu
Smith Colin Peter Sambrook
Tao Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
OSI Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSI Pharmaceuticals LLC filed Critical OSI Pharmaceuticals LLC
Publication of DE602004020073D1 publication Critical patent/DE602004020073D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
DE602004020073T 2003-08-21 2004-08-16 3-substituierte imidazopyridinderivate als c-kit-inhibitoren Active DE602004020073D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49677603P 2003-08-21 2003-08-21
PCT/US2004/026483 WO2005021544A2 (en) 2003-08-21 2004-08-16 N3-substituted imidazopyridine-derivatives as c-kit inhibitors

Publications (1)

Publication Number Publication Date
DE602004020073D1 true DE602004020073D1 (de) 2009-04-30

Family

ID=34272515

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004020073T Active DE602004020073D1 (de) 2003-08-21 2004-08-16 3-substituierte imidazopyridinderivate als c-kit-inhibitoren

Country Status (20)

Country Link
EP (1) EP1658289B1 (de)
JP (1) JP2007502822A (de)
KR (1) KR20060119871A (de)
CN (1) CN1839132A (de)
AP (1) AP2006003552A0 (de)
AR (1) AR045388A1 (de)
AT (1) ATE425977T1 (de)
AU (1) AU2004268950A1 (de)
BR (1) BRPI0413740A (de)
CA (1) CA2536174A1 (de)
DE (1) DE602004020073D1 (de)
IL (1) IL173615A0 (de)
IS (1) IS8318A (de)
MX (1) MXPA06002019A (de)
MY (1) MY138737A (de)
NO (1) NO20060670L (de)
RU (1) RU2006108799A (de)
SG (1) SG131944A1 (de)
TW (1) TW200519111A (de)
WO (1) WO2005021544A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625827D0 (en) * 2006-12-22 2007-02-07 Astex Therapeutics Ltd New compounds
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
SG190620A1 (en) 2008-05-05 2013-06-28 Sanofi Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
EP2308877B1 (de) * 2008-08-05 2014-01-22 Daiichi Sankyo Company, Limited Imidazopyridin-2-on-derivate
WO2010045276A2 (en) * 2008-10-16 2010-04-22 Cara Therapeutics, Inc. Azabenzimidazolones
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
RU2619463C2 (ru) * 2009-12-30 2017-05-16 Аркьюл, Инк. Замещенные имидазопиридинил-аминопиридиновые соединения, полезные при лечении рака
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
JP6046710B2 (ja) * 2011-06-24 2016-12-21 アーキュール，インコーポレイティド 置換されたイミダゾピリジニル−アミノピリジン化合物
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
PL2935248T3 (pl) * 2012-12-21 2018-07-31 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania dla nich
DK3122748T3 (en) * 2014-03-24 2018-11-05 Arqule Inc METHOD OF PREPARING 3- (3- (4- (1-AMINOCYCLOBUTYL) PHENYL) -5-PHENYL-3H-IMIDAZO [4,5-B] PYRIDIN-2-YL) PYRIDIN-2-AMINE
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW251284B (de) * 1992-11-02 1995-07-11 Pfizer
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
WO2001057020A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
AU2002334355A1 (en) * 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
JP2007502822A (ja) 2007-02-15
SG131944A1 (en) 2007-05-28
KR20060119871A (ko) 2006-11-24
WO2005021544A3 (en) 2005-06-16
CA2536174A1 (en) 2005-03-10
NO20060670L (no) 2006-05-12
WO2005021544A2 (en) 2005-03-10
BRPI0413740A (pt) 2006-10-24
IS8318A (is) 2006-02-21
AR045388A1 (es) 2005-10-26
AP2006003552A0 (en) 2006-04-30
AU2004268950A1 (en) 2005-03-10
MY138737A (en) 2009-07-31
ATE425977T1 (de) 2009-04-15
IL173615A0 (en) 2006-07-05
EP1658289B1 (de) 2009-03-18
TW200519111A (en) 2005-06-16
MXPA06002019A (es) 2006-05-31
CN1839132A (zh) 2006-09-27
RU2006108799A (ru) 2006-07-27
EP1658289A2 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
ATE425977T1 (de) 3-substituierte imidazopyridinderivate als c-kit- inhibitoren
ATE388148T1 (de) Chinolinderivate als phosphodiesterase inhibitoren
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
ATE481402T1 (de) Pyrazolopyridin-derivate
DE60317529D1 (de) Imidazopyridine als hemmstoffe cyclin abhängiger kinasen
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE415400T1 (de) Pyrazolopyridinderivate
DE60304911D1 (de) Xanthin-Derivate als DPP-IV-Inhibitoren
ATE437876T1 (de) Hexahydropyridoisochinoline als dpp-iv- inhibitoren
ATE330957T1 (de) Carbamat-substituierte pyrazolopyridine
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE378049T1 (de) Nicotinamid-derivate als pde4-hemmer
ATE386730T1 (de) Phenylpiperazinderivate als serotonin wiederaufnahmehemmer
DE60336732D1 (de) Azaindol-kinaseinhibitoren
ATE478868T1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
DE602004017623D1 (de) N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitoren
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
ATE529428T1 (de) Thioxanthinderivate als myeloperoxidaseinhibitoren
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
ATE292115T1 (de) Indolderivate als cox-ii-inhibitoren
ATE538787T1 (de) Benzimidazol-derivative als raf-kinase-hemmer
ATE362930T1 (de) Nicotinamid-derivate verwendbar als pde4 inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition